Needham Maintains Buy on Artivion, Lowers Price Target to $29
Needham analyst Mike Matson maintains Artivion (NYSE:AORT) with a Buy and lowers the price target from $30 to $29.
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Artivion Q4 Sales $79.39M Beat $77.76M Estimate
Artivion (NYSE:AORT) reported quarterly sales of $79.39 million which beat the analyst consensus estimate of $77.76 million by 2.10 percent. This is a 16.93 percent increase over sales of $67.90 million the same period
Earnings Scheduled For February 17, 2022
Companies Reporting Before The Bell
• Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million.